TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 29414377

Group type: EXPERIMENTAL
Intervention: Light (illuminated LED fixture)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Dark (unilluminated LED fixture)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Baseline (no lighting fixture)
Number of subjects: 15
Study: 26679443

Group type: EXPERIMENTAL
Intervention: Text message notification within 24 hours of receipt of abnormal mammogram
Number of subjects: 29

Group type: COMPARATOR
Intervention: Delayed text message notification (4 weeks later)
Number of subjects: 29
Study: 24464788

Group type: EXPERIMENTAL
Intervention: Enalapril
Number of subjects: 6797

Group type: COMPARATOR
Intervention: Control group (no enalapril)
Number of subjects: 6797
Study: 23044035

Group type: EXPERIMENTAL
Intervention: 8-week dairy intake intervention via electronic mail
Number of subjects: 211

Group type: COMPARATOR
Intervention: Stress management intervention via electronic mail
Number of subjects: 211
Study: 19156626

Group type: EXPERIMENTAL
Intervention: Acarbose (alpha-glucosidase inhibitor)
Number of subjects: 1368

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1368
Study: 17194889

Group type: EXPERIMENTAL
Intervention: Bezafibrate
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Fenofibrate
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control (Placebo)
Number of subjects: 0

Group type: COMPARATOR
Intervention: PPARalpha-deficient mice and adipocytes
Number of subjects: 0
Study: 14668187

Group type: EXPERIMENTAL
Intervention: Centrifugal pump
Number of subjects: 34

Group type: COMPARATOR
Intervention: Roller pump
Number of subjects: 34
Study: 11200923

Group type: EXPERIMENTAL
Intervention: Haemodialysis
Number of subjects: 22
Study: 8776746

Group type: EXPERIMENTAL
Intervention: Brofaromine (CGP 11,305 A), a selective and reversible MAO A inhibitor
Number of subjects: 0

Group type: COMPARATOR
Intervention: Nonparametric Wilcoxon signed-rank test
Number of subjects: 0

Group type: COMPARATOR
Intervention: ANOVA of transformed data
Number of subjects: 0
Study: 1470044

Group type: EXPERIMENTAL
Intervention: 17 beta‐oestradiol 10 micrograms
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: 17 beta‐oestradiol 25 micrograms
Number of subjects: 24
Study: 6376292

Group type: EXPERIMENTAL
Intervention: Tripotassium dicitrato bismuthate (TDB) tablet four times a day
Number of subjects: 25

Group type: COMPARATOR
Intervention: High dose cimetidine (1.6 g daily)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Tripotassium dicitrato bismuthate (TDB) after crossover
Number of subjects: 25

Group type: COMPARATOR
Intervention: High dose cimetidine after crossover
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Overall comparison
Number of subjects: 25
Study: 30653704

Group type: EXPERIMENTAL
Intervention: Structured self-monitoring of blood glucose alone (n=147)
Number of subjects: 446

Group type: EXPERIMENTAL
Intervention: Structured self-monitoring of blood glucose plus TeleCare (n=148)
Number of subjects: 446

Group type: COMPARATOR
Intervention: Control group receiving usual diabetes care (n=151)
Number of subjects: 446

Group type: COMPARATOR
Intervention: Structured self-monitoring of blood glucose compared to control group
Number of subjects: 446
Study: 29281941

Group type: EXPERIMENTAL
Intervention: Action planning and coping planning intervention strategies; duration: 105 days; includes in-person meetings and phone calls to reinforce the intervention.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual care from the health unit; duration: 105 days.
Number of subjects: 0
Study: 25040485

Group type: EXPERIMENTAL
Intervention: Hospital value‐based purchasing (HVBP) program
Number of subjects: 0

Group type: COMPARATOR
Intervention: Nonexposed hospitals (control group)
Number of subjects: 0
Study: 24056820

Group type: EXPERIMENTAL
Intervention: Ruxolitinib
Number of subjects: 1

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1

Group type: COMPARATOR
Intervention: Best available therapy
Number of subjects: 1
Study: 19638470

Group type: EXPERIMENTAL
Intervention: Liraglutide
Number of subjects: 0
Study: 16923435

Group type: EXPERIMENTAL
Intervention: Intervention group (n = 199) received optimized nonpharmacological and pharmacological cardiovascular treatments by a geriatrician according to guidelines.
Number of subjects: 400

Group type: COMPARATOR
Intervention: Control group (n = 201) received usual care.
Number of subjects: 400
Study: 17076970

Group type: EXPERIMENTAL
Intervention: Escitalopram
Number of subjects: 1636

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1636
Study: 11212063

Group type: EXPERIMENTAL
Intervention: Amlodipine 5 mg
Number of subjects: 199

Group type: EXPERIMENTAL
Intervention: Felodipine ER 5 mg
Number of subjects: 199

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 199

Group type: EXPERIMENTAL
Intervention: Amlodipine or Felodipine
Number of subjects: 199
Study: 8859608

Group type: EXPERIMENTAL
Intervention: Saline 0.9% rinses
Number of subjects: 0

Group type: COMPARATOR
Intervention: Hydrogen peroxide 3.5 volumes (HP) rinses
Number of subjects: 0
Study: 1643912

Group type: EXPERIMENTAL
Intervention: Methacholine inhalation challenge (MIC)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Eucapnic voluntary hyperventilation (EVH) with dry gas
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Eucapnic voluntary hyperventilation (EVH) with cold gas
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Bicycle ergometer challenge
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Receiver operating characteristic curves for EVH techniques and MIC
Number of subjects: 40
Study: 6825410

Group type: EXPERIMENTAL
Intervention: Chest cage restriction (strapped in the position of full expiration)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Normal breathing without chest cage restriction (control)
Number of subjects: 6
Study: 30506299

Group type: COMPARATOR
Intervention: PCEA
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: PIEB
Number of subjects: 200
Study: 30144554

Group type: EXPERIMENTAL
Intervention: Cryptogenic cirrhosis
Number of subjects: 247

Group type: COMPARATOR
Intervention: NASH cirrhosis
Number of subjects: 247
Study: 27339251

Group type: EXPERIMENTAL
Intervention: Bolus feeding (Group A)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Continuous feeding (Group B)
Number of subjects: 40
Study: 24170758

Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy for adherence and depression (CBT-AD)
Number of subjects: 87
Study: 22038792

Group type: EXPERIMENTAL
Intervention: Tamsulosin (0.2 mg) once daily
Number of subjects: 104
Study: 20386475

Group type: EXPERIMENTAL
Intervention: 1.5 g arginine + 300 mg grape seed extract
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: 3.0 g arginine + 300 mg grape seed extract
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo (microcrystalline cellulose)
Number of subjects: 50
Study: 18339679

Group type: EXPERIMENTAL
Intervention: 100 mg aspirin on alternate days
Number of subjects: 37270

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 37270
Study: 15963082

Group type: EXPERIMENTAL
Intervention: Lansoprazole 30 mg twice daily
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Lansoprazole 30 mg twice daily plus famotidine 20 mg twice daily
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 12908901

Group type: EXPERIMENTAL
Intervention: Supplemental intakes of 0.3, 1.0 and 2.0 g EPA+DHA/d
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Antioxidant co-supplementation (200 microg Se, 3 mg Mn, 30 mg D-alpha-tocopheryl succinate, 90 mg ascorbic acid, 450 microg vitamin A)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study: 10232721

Group type: EXPERIMENTAL
Intervention: Cuffed oropharyngeal airway (COPA)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Laryngeal mask airway (LMA)
Number of subjects: 80
Study: 8916621

Group type: EXPERIMENTAL
Intervention: 8 sessions of time-limited psychotherapy
Number of subjects: 212

Group type: EXPERIMENTAL
Intervention: 16 sessions of time-limited psychotherapy
Number of subjects: 212

Group type: EXPERIMENTAL
Intervention: Both 8 and 16 sessions
Number of subjects: 212
Study: 1865542

Group type: EXPERIMENTAL
Intervention: E5 murine monoclonal antibody (2 mg/kg)
Number of subjects: 486

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 486
Study: 31727667

Group type: EXPERIMENTAL
Intervention: Choosing Wisely Australia 5 Questions resource and preparation video
Number of subjects: 0

Group type: COMPARATOR
Intervention: Choosing Wisely Australia 5 Questions resource
Number of subjects: 0

Group type: COMPARATOR
Intervention: Preparation video
Number of subjects: 0
Study: 28625860

Group type: EXPERIMENTAL
Intervention: Telephone counseling
Number of subjects: 71

Group type: COMPARATOR
Intervention: Routine care (Control)
Number of subjects: 71
Study: 25926387

Group type: COMPARATOR
Intervention: Serum eicosapentaenoic acid (EPA)
Number of subjects: 438

Group type: COMPARATOR
Intervention: Serum docosahexaenoic acid (DHA)
Number of subjects: 438

Group type: COMPARATOR
Intervention: Serum linoleic acid
Number of subjects: 438

Group type: COMPARATOR
Intervention: Serum trans fatty acids
Number of subjects: 438

Group type: EXPERIMENTAL
Intervention: Serum arachidonic acid
Number of subjects: 438
Study: 23799810

Group type: EXPERIMENTAL
Intervention: Experimental treatment
Number of subjects: 0

Group type: COMPARATOR
Intervention: Active reference treatment
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 20936566

Group type: EXPERIMENTAL
Intervention: Hungry state (hot)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Satiated state (cold)
Number of subjects: 0
Study: 20639717

Group type: EXPERIMENTAL
Intervention: Lactobacillus reuteri ATCC 55730 (probiotic supplementation)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo (control)
Number of subjects: 0
Study: 18437790

Group type: EXPERIMENTAL
Intervention: Immediate or early loaded implants
Number of subjects: 22

Group type: COMPARATOR
Intervention: Conventional loading period
Number of subjects: 22
Study: 15134615

Group type: EXPERIMENTAL
Intervention: TNF-alpha inhibitors (etanercept and infliximab)
Number of subjects: 31

Group type: COMPARATOR
Intervention: No TNF-alpha inhibition therapy (Control Group 2)
Number of subjects: 31
Study: 12351257

Group type: EXPERIMENTAL
Intervention: 6% hydroxyethyl starch 200/0.5 (HES)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: 4% modified gelatin (GEL)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Lactated Ringer's solution (RL)
Number of subjects: 60
Study: 9647031

Group type: EXPERIMENTAL
Intervention: Glutamine 4 g/day
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Glutamine 8 g/day
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 7807504

Group type: EXPERIMENTAL
Intervention: Quinapril (10-40 mg twice daily) in Study I; titrated every 1-2 weeks for 6 weeks, followed by 6 weeks of therapy.
Number of subjects: 172

Group type: EXPERIMENTAL
Intervention: Quinapril (5-20 mg twice daily) in Study II; titrated every 4 weeks for 16 weeks, followed by a 12-week maintenance period.
Number of subjects: 172
Study: 2642814

Group type: EXPERIMENTAL
Intervention: Ortho Novum 777 (norethindrone)
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Triphasil (levonorgestrel)
Number of subjects: 61
Study: 790547

Group type: EXPERIMENTAL
Intervention: Ketoprofen 150 mg daily
Number of subjects: 38

Group type: COMPARATOR
Intervention: Phenylbutazone 300 mg daily
Number of subjects: 38
Study: 31190590

Group type: EXPERIMENTAL
Intervention: SAFETY intervention (home-based disease management including community-based AF care and home visits)
Number of subjects: 335

Group type: COMPARATOR
Intervention: Standard management (routine primary healthcare and hospital outpatient follow-up)
Number of subjects: 335
Study: 28279207

Group type: EXPERIMENTAL
Intervention: Getting To Outcomes (GTO) implementation support strategy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Implementation as Usual (IU)
Number of subjects: 0
Study: 25208649

Group type: EXPERIMENTAL
Intervention: Maternal responsiveness rated on a five-point global rating scale (1 = very low responsiveness, 5 = very high responsiveness)
Number of subjects: 301
Study: 24427599

Group type: COMPARATOR
Intervention: Myringoplasty only (Group A)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Cortical mastoidectomy with myringoplasty (Group B)
Number of subjects: 120
Study: 21523849

Group type: EXPERIMENTAL
Intervention: Healthcare professionals who deliver babies (OBs and MWs)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Healthcare professionals who only do prenatal consultations (GYNs and GPs)
Number of subjects: 100
Study: 19232037

Group type: EXPERIMENTAL
Intervention: Dexlansoprazole MR 30 mg
Number of subjects: 83

Group type: EXPERIMENTAL
Intervention: Dexlansoprazole MR 90 mg
Number of subjects: 83

Group type: EXPERIMENTAL
Intervention: Dexlansoprazole MR 120 mg
Number of subjects: 83

Group type: COMPARATOR
Intervention: Lansoprazole 30 mg
Number of subjects: 83

Group type: COMPARATOR
Intervention: Lansoprazole 15 mg
Number of subjects: 83
Study: 16428050

Group type: EXPERIMENTAL
Intervention: Single-phase contrast medium injection (Group 1)
Number of subjects: 244

Group type: EXPERIMENTAL
Intervention: Dual-phase contrast medium injection (Group 2)
Number of subjects: 244

Group type: EXPERIMENTAL
Intervention: Three-phase injection (Group 3)
Number of subjects: 244
Study: 14527372

Group type: EXPERIMENTAL
Intervention: Remifentanil
Number of subjects: 54

Group type: COMPARATOR
Intervention: Fentanyl
Number of subjects: 54
Study: 10636157

Group type: EXPERIMENTAL
Intervention: Transdermal selegiline
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 8884561

Group type: EXPERIMENTAL
Intervention: Nifedipine (20 mg)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Captopril (25 mg)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Diazoxide (150 mg)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 1362843

Group type: EXPERIMENTAL
Intervention: Bifonazole shampoo
Number of subjects: 44

Group type: COMPARATOR
Intervention: Vehicle shampoo
Number of subjects: 44
Study: 3910546

Group type: EXPERIMENTAL
Intervention: Acyclovir 200 mg four times a day
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 31885221

Group type: EXPERIMENTAL
Intervention: RUSF
Number of subjects: 485

Group type: COMPARATOR
Intervention: Control
Number of subjects: 485

Group type: EXPERIMENTAL
Intervention: Low consumers of RUSF
Number of subjects: 485

Group type: COMPARATOR
Intervention: CSB++ or MNP
Number of subjects: 485
Study: 30079863

Group type: EXPERIMENTAL
Intervention: Nicotine preloading with a 21 mg/24 hour nicotine patch for 4 weeks prior to quit date
Number of subjects: 1792

Group type: COMPARATOR
Intervention: Control group received equivalent behavioral support
Number of subjects: 1792
Study: 27197192

Group type: EXPERIMENTAL
Intervention: Trastuzumab and chemotherapy
Number of subjects: 48
Study: 24766817

Group type: EXPERIMENTAL
Intervention: Warfarin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Dabigatran
Number of subjects: 0
Study: 22290743

Group type: EXPERIMENTAL
Intervention: Rivastigmine (4.6 mg/24 hours for 3 weeks)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 21336011

Group type: EXPERIMENTAL
Intervention: Subjective measurement via Hot Flash Diary Report
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Objective measurement using Mexameter, Skin Thermometer, Corneometer, and LDPI
Number of subjects: 100
Study: 19020639

Group type: EXPERIMENTAL
Intervention: Bimatoprost 0.03% drops (1 drop given preoperatively)
Number of subjects: 85

Group type: COMPARATOR
Intervention: Placebo (balanced saline solution, 1 drop given preoperatively)
Number of subjects: 85

Group type: EXPERIMENTAL
Intervention: Bimatoprost 0.03% drops
Number of subjects: 85

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 85
Study: 16363755

Group type: EXPERIMENTAL
Intervention: Total Vaginal Hysterectomy (TVH)
Number of subjects: 158

Group type: EXPERIMENTAL
Intervention: Transvaginal Sacrospinous Uterine Suspension (SSUS)
Number of subjects: 158
Study: 12063524

Group type: EXPERIMENTAL
Intervention: Desloratadine 5 mg
Number of subjects: 47

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 47
Study: 10328861

Group type: EXPERIMENTAL
Intervention: Onset/rime segmentation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Phonemic segmentation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Whole word repetition
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Onset/rime training
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Phoneme training
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Word level training
Number of subjects: 0
Study: 8577211

Group type: EXPERIMENTAL
Intervention: Metformin after low protein breakfast
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Metformin after low fat breakfast
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Metformin after low carbohydrate breakfast
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Metformin after standard breakfast
Number of subjects: 17

Group type: COMPARATOR
Intervention: Fasting conditions
Number of subjects: 17
Study: 2251616

Group type: EXPERIMENTAL
Intervention: Bromocriptine (Parlodel; Sandoz) in doses up to 26 mg daily
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Bromocriptine (Parlodel; Sandoz) in doses beyond 25-30 mg daily
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Bromocriptine (Parlodel; Sandoz) with slow dose increases
Number of subjects: 0
Study: 425546

Group type: EXPERIMENTAL
Intervention: Endoxan
Number of subjects: 8

Group type: COMPARATOR
Intervention: Control group (no considerable treatment)
Number of subjects: 8
Study: 31575021

Group type: EXPERIMENTAL
Intervention: Oral Vitamin A&D supplement (20,000 IU retinyl palmitate and 2000 IU cholecalciferol)
Number of subjects: 79

Group type: COMPARATOR
Intervention: Matched placebo
Number of subjects: 79
Study: 29878061

Group type: EXPERIMENTAL
Intervention: HMBF (0.81 kcal/mL)
Number of subjects: 127

Group type: COMPARATOR
Intervention: BMBF (0.72 kcal/mL)
Number of subjects: 127

Group type: EXPERIMENTAL
Intervention: HMBF
Number of subjects: 127

Group type: COMPARATOR
Intervention: BMBF
Number of subjects: 127
Study: 26881417

Group type: COMPARATOR
Intervention: Control group with daily feedback
Number of subjects: 281

Group type: EXPERIMENTAL
Intervention: Gain incentive ($1.40 for achieving the goal)
Number of subjects: 281

Group type: EXPERIMENTAL
Intervention: Lottery incentive (daily eligibility for approximately $1.40 if goal achieved)
Number of subjects: 281

Group type: EXPERIMENTAL
Intervention: Loss incentive ($42 allocated monthly upfront, $1.40 removed for each day the goal is not achieved)
Number of subjects: 281
Study: 25222630

Group type: EXPERIMENTAL
Intervention: Cognitive rehabilitation and multi-family group treatment (CR-MFG)
Number of subjects: 46

Group type: COMPARATOR
Intervention: Standard care (SC)
Number of subjects: 46
Study: 22828532

Group type: EXPERIMENTAL
Intervention: Methotrexate
Number of subjects: 56

Group type: COMPARATOR
Intervention: Hydroxychloroquine
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Both Methotrexate and Hydroxychloroquine
Number of subjects: 56
Study: 20797407

Group type: EXPERIMENTAL
Intervention: Intravenous micafungin (MCFG) 150-300 mg once daily
Number of subjects: 107

Group type: COMPARATOR
Intervention: Intravenous voriconazole (VRCZ) 6 mg/kg twice on Day 1 followed by 4 mg/kg twice daily
Number of subjects: 107
Study: 17908614

Group type: EXPERIMENTAL
Intervention: 5 days of select cephalosporins (cefpodoxime, cefuroxime, cefotiam, and cefdinir)
Number of subjects: 1030

Group type: COMPARATOR
Intervention: 10 days of penicillin
Number of subjects: 1030
Study: 16231620

Group type: EXPERIMENTAL
Intervention: Phosphorylcholine (PC) coated oxygenators (Group B)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Non-coated oxygenators (Group A)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Both groups (Group A and Group B)
Number of subjects: 40
Study: 11867369

Group type: EXPERIMENTAL
Intervention: IV tramadol (150‐mg bolus followed by infusion, total 450 mg/24 h)
Number of subjects: 89

Group type: EXPERIMENTAL
Intervention: Epidural morphine (2 mg, then 0.2 mg/h)
Number of subjects: 89

Group type: COMPARATOR
Intervention: PCA morphine only
Number of subjects: 89

Group type: EXPERIMENTAL
Intervention: IV tramadol
Number of subjects: 89
Study: 7593870

Group type: EXPERIMENTAL
Intervention: Individualized cognitive treatment (CT)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Self-help support group (SG)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Symptom-monitoring waiting-list control (WL)
Number of subjects: 34
Study: 1958108

Group type: EXPERIMENTAL
Intervention: ivermectin 100 mcg/kg
Number of subjects: 58

Group type: COMPARATOR
Intervention: DEC 3 mg/kg
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: ivermectin 100 mcg/kg or DEC 3 mg/kg (2 successive doses)
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: ivermectin 100 mcg/kg or DEC 3 mg/kg
Number of subjects: 58
Study: 6211296

Group type: EXPERIMENTAL
Intervention: sulfinpyrazone, 800 mg/day
Number of subjects: 44

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 44
Study: 30869743

Group type: EXPERIMENTAL
Intervention: Prophylactic cranial irradiation (PCI)
Number of subjects: 340

Group type: COMPARATOR
Intervention: Observation
Number of subjects: 340
Study: 27682415

Group type: EXPERIMENTAL
Intervention: Guided ICBT
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Unguided ICBT
Number of subjects: 150

Group type: COMPARATOR
Intervention: Guided and Unguided ICBT
Number of subjects: 150
Study: 26609167

Group type: EXPERIMENTAL
Intervention: Vitamin D supplementation (50 kIU/week)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 25432688

Group type: EXPERIMENTAL
Intervention: Uterine artery embolization (UAE)
Number of subjects: 216

Group type: COMPARATOR
Intervention: Myomectomy
Number of subjects: 216
Study: 22157240

Group type: EXPERIMENTAL
Intervention: Probiotic mixture (Lactobacillus acidophilus, Lactobacillus plantarum, Lactobacillus rhamnosus, Bifidobacterium breve, Bifidobacterium lactis, Bifidobacterium longum, and Streptococcus thermophilus 1.0×10 CFU) taken daily for 8 weeks
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Probiotic mixture
Number of subjects: 50
Study: 20569037

Group type: EXPERIMENTAL
Intervention: Tapas Acupressure Technique (TAT)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Self-directed social support comparison intervention
Number of subjects: 0
Study: 18037747

Group type: EXPERIMENTAL
Intervention: Continuous RF delivery
Number of subjects: 40

Group type: COMPARATOR
Intervention: Point-by-point RF ablation
Number of subjects: 40